TVRD
Tvardi Therapeutics, Inc.
NASDAQ: TVRD · HEALTHCARE · BIOTECHNOLOGY
$3.15
+2.94% today
Updated 2026-04-30
Market cap
$30.02M
P/E ratio
—
P/S ratio
559.61x
EPS (TTM)
$-3.26
Dividend yield
—
52W range
$3 – $44
Volume
0.0M
Tvardi Therapeutics, Inc. (TVRD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $135.08M | $23.03M | $41.87M | $20.97M | $7.14M | $0.00 |
| Revenue growth (YoY) | — | -83.0% | +81.8% | -49.9% | -66.0% | -100.0% |
| Cost of revenue | — | $1.55M | $7.51M | $6.43M | $812000.00 | $95000.00 |
| Gross profit | — | $21.47M | $34.35M | $14.54M | $6.33M | $-95000.00 |
| Gross margin | 0.0% | 93.3% | 82.1% | 69.3% | 88.6% | — |
| R&D | $107.74M | $82.58M | $91.76M | $108.38M | $32.76M | $18.01M |
| SG&A | — | — | $2.73M | $2.80M | $4.46M | $8.74M |
| Operating income | $5.38M | $-89.08M | $-87.53M | $-121.50M | $-55.78M | $-26.75M |
| Operating margin | 4.0% | -386.8% | -209.1% | -579.4% | -781.6% | — |
| EBITDA | $8.73M | $-86.89M | $-83.80M | $-117.65M | $-62.60M | $-26.65M |
| EBITDA margin | 6.5% | -377.3% | -200.2% | -561.1% | -877.1% | — |
| EBIT | $7.72M | $-88.44M | $-85.47M | $-117.91M | $-62.79M | $-26.75M |
| Interest expense | — | — | $3000.00 | $0.00 | $8.47M | — |
| Income tax | $-691000.00 | — | — | — | $-398000.00 | — |
| Effective tax rate | -9.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% |
| Net income | $8.41M | $-88.44M | $-85.47M | $-118.51M | $-70.87M | $-18.21M |
| Net income growth (YoY) | — | -1151.6% | +3.4% | -38.7% | +40.2% | +74.3% |
| Profit margin | 6.2% | -384.1% | -204.2% | -565.2% | -993.0% | — |